Jian Feng

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 230 citations

Medicine, Oncology, Pharmacology +13

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li et al. · Journal of Clinical Oncology · 2022 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17

Surgical techniques for early-stage thymoma: Video-assisted thoracoscopic thymectomy versus transsternal thymectomy

Bo Ye, Jicheng Tantai, Xiaoxiao Ge et al. · Journal of Thoracic and Cardiovascular Surgery · 2013 · 118 citations · Full text

Medicine, Surgery, Oncologic Surgery +8

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)

Zhiyuan Tang, Qin Shen, Hao Xie et al. · Oncotarget · 2016 · 112 citations · Full text

Medicine, Oncology, Pharmacokinetics +11

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

Yuankai Shi, Shucai Zhang, Xingsheng Hu et al. · Journal of Thoracic Oncology · 2020 · 109 citations · Full text

Medicine, Oncology, Pharmacology +15